• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Syngene

    Cytovance Biologics

    Baxter BioPharma Solutions

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Reed-Lane

    Baxter BioPharma Solutions

    Syngene

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Aseptic Fill/Finish Roundtable

    Business leaders address aseptic fill/finish market trends, challenges and growth opportunities

    Aseptic Fill/Finish Roundtable
    Photo courtesy of LSNE
    Related CONTENT
    • Symbiosis
    • Asymchem
    • PCI Pharma Services
    • Piramal Pharma Solutions
    • Bora Pharmaceuticals
    Tim Wright, Editor, Contract Pharma 11.09.16
    The last step of the injectable drug manufacturing process, fill/finish, is often characterized as the most critical step in drug manufacturing due to its highly specialized nature, which makes it difficult getting products to market or clinical trials. In addition to being extremely costly, fill/finish operations are subject to extreme scrutiny by regulatory agencies.

    For this panel discussion, Contract Pharma talked to some of the leading players in the fill/finish space, including Catalent, LSNE, Piramal, Symbiosis and PCI, to discuss market and technology trends, and get an overall feel for where the market is headed.

    Contract Pharma: How would you describe the current state of the aseptic fill/finish outsourcing market?
    Carole Delauney, account director, drug delivery solutions, Catalent:
    It appears to us that the aseptic fill/finish outsourcing market is, and looks to remain, very healthy. The growth of generic injectables appears to be outpacing that of innovator products. Biotech firms, unless very well funded, will always seek to outsource fill/finish. Even if successful developments will eventually be out-licensed to large pharma, who may have spare capacity, securing the supply chain with an experienced partner will likely have a positive impact on the value of the deal. Indeed, the scale-up phases of some processes or drug substance handling are so complex, that the choice of the right fill/finish partner for phase III trials and commercial supply may be an asset and add value to the program.

    The outsourcing strategies of large pharma companies vary from one company to another and sometimes corporate strategy, for example, toward facility utilization, may take precedence over the specific needs of an individual program. Large pharma tends to outsource fill/finish of established products, which are perhaps nearing the end of their lifespan or that are of lower strategic importance, whilst keeping more strategically important product manufacturing in-house. However, pharma companies still have an interest in outsourcing where specific expertise is not available in-house, or when they want to secure their supply chain network with a second source. Also, in-house investments can be at higher risk compared to a CDMO’s business model, because excess capacity is more likely to remain underutilized within pharma’s own network.

    Joanne Anderson, business development director, Symbiosis Pharmaceutical Services: The last few years have seen some major changes to the aseptic fill/finish landscape. The market will continue to change and evolve, but as ever, customers are faced with the choice of engaging a big one-stop-shop service provider or electing to go with a smaller, more specialist, flexible and time-conscious partners. Ultimately for clients, it’s about getting to clinical trials in the safest and quickest route they possibly can. We believe there is significant market demand for aseptic manufacturing capabilities for biologics, highly potent APIs and small molecules, due to the increased number of oncology products requiring containment capabilities.

    The level of growth within the biotech sector is driving a surge in demand for aseptically processed parenteral drug products. There is a positive investment climate in the biotech space, which is facilitating the development of new biological drugs, increasing the depth of an industry-wide drug pipeline and fueling demand for outsourced manufacturing services to bring products to clinical trial stage. With biotech companies, we are seeing more and more coming to us at the late preclinical drug development stage so they can start planning production in line with clinical milestones.

    Lonny White, chief operating officer, Piramal Pharma Solutions: Aseptic fill/finish outsourcing continues to be a growing market, particularly for hi-tech service offerings—lyophilization, potent compound manufacturing and complex formulations. Growth will continue in the generics market, mainly fueled by a 13% growth in China, 6% growth in the U.S., and 12% among remaining emerging markets. Moving forward, emerging markets will pose a greater threat to CDMOs as they mature and stabilize, and growth in developing markets continues in general. However, concerns with quality and reliability of supply persist in these emerging markets.

    Justin Schroeder, executive diretor marketing, business development, PCI Pharma Services: The market is certainly strong by virtue of growth in biologics and biosimilars. Drug companies are increasingly reliant on CMOs to support the trend towards complexity and customization in delivery forms. The infrastructure needed to support these products is considerable. CMOs play a vital role in defraying capital costs and providing expertise in bringing new products to market quickly and effectively, for development stages, clinical trials, as well as commercial supply.

    Christine Palus, vice president, sales and marketing, Lyophilization Services of New England (LSNE): Fill/finish is historically one of the most outsourced activities due to the high cost of equipment, quality and facility requirements. Many CMOs have experienced a surge in the market due to several factors, including the decrease in the amount of high-quality CMO capacity available for aseptic fill/finish. There have been a number of CMOs that have had compliance issues and experienced lengthy shut-downs or have gone out of business altogether, so currently there are fewer established and reliable CMOs available for fill/finish. Additionally, we have seen many small and mid-sized companies get acquired by global pharma companies or merged with other CMOs to expand their upstream or downstream services, as many are moving towards the one-stop-shop model. Some large pharmaceutical companies have also decided to build their own fill sites, which has reduced or eliminated their need for a filling CMO.

    CP: What pharma/biopharma macro trends are you seeing and how are they trickling down to impact aseptic fill/finish operations?
    Delauney, Catalent:
    Our experience is of continued strong interest in injectables, despite constant innovation to bring more non-invasive dose forms to market, and outsourcing of vaccines, biologics and biosimilars appears to be keeping the injectables pipeline buoyant. It has been estimated that the market has shifted from just one of the top ten marketed pharmaceuticals being delivered by injection ten years ago, to seven out of the 10 today.

    With the complexity of biosimilar regulatory approval, biologically-derived drugs have a longer lifespan on the market compared to small molecule drugs. When a biosimilar does reach market, its impact on the market share of the originator’s product is less than what was typical for small molecule blockbusters in the past, and market prices for biosimilars remain high compared with those for small molecule generics. Both situations are beneficial for CMOs and CDMOs involved in such fill/finish projects.

    Finally, patient compliance is being improved with the use of drug delivery devices or new formulation technologies, with the advantages of fewer dosing errors, lower dose frequency, or reduced side effects. This innovation may confer a second life to generic drugs and extended patent life and retained market share. Therefore, I believe that the trend for injectables is still very strong and promising.

    Anderson, Symbiosis: There is increased emphasis on the development of treatments for small patient populations in the case of orphan indications and novel tailored personalized medicines. Such products require specific capabilities and experience in GMP manufacturing for small-scale sterile batches for clinical evaluations, hence trickling down to what we do at Symbiosis. Furthermore, having specific experience in handling biologic drug substances is a significant advantage for a specialist CMO as many of these new entities require aseptic fill finish.

    White, Piramal: Lyophilization capacity for potent products is expected to become tight unless there is significant expansion of capacity. Demand for aseptic manufacturing has outstripped supply in the market place, particularly for cytotoxic products. Demand for potent generic products for the U.S. should plateau as products restore supply through new ANDAs. For example, U.S. demand will likely continue to grow as underserved markets try to catch up. Various acquisitions have changed the competitive landscape of aseptic manufacturing capacity. Large players in the pharmaceutical industry, particularly generic players, have taken to buying capacity to ensure their future. In addition, quality and regulatory issues at CDMOs persist for both U.S. and ex-U.S. manufacturing sites, while expansion of active drug substance manufacturers into contract manufacturing space offering end-to-end service is growing.

    Schroeder, PCI: There is significant growth in both biologics generally, as well as biosimilar development activity. A recent IMS study identified over 50 distinct biosimilars in development. Likewise, IMS reports that over 37% of all drugs in pipeline development are biologics. From a packaging perspective, this has led to considerable need for solutions for vials, and increasingly prefilled syringes that require some level of assembly at our sites such as plunger rod, finger flange, labeling, etc. Demand is also increasing for prefilled syringes that require additional assembly for safety devices and ancillary add-on technologies to improve the patient experience. Downstream we are often placing these vials and syringes into complex kits with multiple components such as various gauge needles, transfer devices and safety caps, instructions for use, regulatory literature, alcohol pads, and other inclusions specific to the drug. We use sophisticated vision systems to ensure the presence and correctness of each component throughout the process as accuracy is paramount. This growth in parenteral delivery forms also requires considerable capacity and knowledge of best practices for supporting these high value, cold chain medicines, and in some instances actually requires packaging in a cold chain environment if the product has no allowable excursion time. It takes a depth of expertise to ensure a safe and effective supply chain.

    Palus, LSNE: The pharma/biopharma industry is an ever-evolving industry and these changes inevitably affect aseptic fill/finish CMOs. Overall, we have experienced a rise in the volume of incoming business over the last couple of years due in part to an increase in the amount of R&D spending and NDA submissions, which has affected both LSNE’s development services as well as our GMP filling services. One specific factor contributing to the rise in business is the greater number of biosimilars in development, which require fill/finish capabilities. The number of Orphan Designated Drugs (ODD) has also increased significantly so there is less focus on capacity and more focus on technologies, timelines and quality. There are not as many blockbuster drugs being developed and the need for small to mid-size batches is increasing. 

    We have also seen more stringent requirements from the regulatory bodies, and aseptic fill/finish has been one of the main areas of focus. This additional scrutiny has caused many CMOs to either exit the business or invest in their facilities and employees in order to remain compliant. With tighter requirements at CMOs, the cost associated with outsourcing has continued to grow. This is causing some large and medium-sized companies to make the investment to bring on in-house manufacturing capabilities. 

    Other changes in the industry have been the increase in the number of combination products being developed. These types of products require a QA staff that is well versed in a range of regulatory requirements from both the drug/biologic product and the medical device guidances, which can be a challenge. We also foresee an increase in the number of products for animal use needing higher quality cGMP aseptic fill/finish. The level of scrutiny for veterinarian drugs is ever increasing so companies are outsourcing their drugs to CMOs with robust quality systems that can meet CVM guidance.  

    CP: What are the most important trends in aseptic fill/finish outsourcing today?
    Delauney, Catalent:
    Demands differ from one market to another. For instance, ampoules are not a U.S. preference but they are manufactured by the millions in Europe. Vial filling—liquid and lyophilization—remains the largest portion of the fill/finish market at both the development and commercial stages. With some macromolecule products reaching later development phases, I have noticed increasing demands from biotech/pharma companies planning to secure their supply chain network through qualification of a second manufacturing site. Also, with the development of technologies enabling self-injections and the need to decrease the number of preparation steps for injectables, the trend for pre-filled syringes is still on the rise.

    Time and flexibility often have a very high influence on the selection of a fill/finish CDMO partner, and after the often lengthy and expensive process of securing drug substance manufacturing, clients can sometimes underestimate the complexity of setting up fill/finish operations that are suitable and scalable. This also means they may have unreasonable expectations of the cost and time required to find an optimal solution. We are however seeing more experienced innovators engaging external support earlier in development, and some are seeking more strategic relationships that begin at an early stage of development but take into account the needs of later stage supply. With the increasing proportion of orphan drug development going on, the need for flexibility when market demands or forecasts change, for example when follow-on indications are launched, CDMOs often prove their experience by adapting to their client’s needs.

    With the shift from the historical blockbuster model towards the more frequent focus on smaller batch sizes and personalized medicines, flexibility in the manufacturing environment is again necessary. To name a few examples, the use of a restricted access barrier system (RABS), as a viable alternative to isolators in reducing human intervention in a controlled environment, is better suited to multiple product filling lines and may simplify primary container format changes. In addition, single-use equipment, as opposed to traditional multi-use stainless steel tanks, has also had a positive impact on overall project timing.

    Anderson, Symbiosis: Success in outsourcing is underpinned by technical capabilities and effective communication on both sides of the supply contract. In addition, the relationship between the client and service provider is fundamental. We are seeing more and more clients moving away from tactical outsourcing initiatives in favor of a relationship-oriented strategic partnership with CMO partners across a collaborative supply chain. Due to the nature and complexity of sterile fill finish, most drug developers need a long-term vendor that will invest time, energy and resource into achieving a productive outcome. The long-term benefit for a CMO like Symbiosis is we grow and scale-up as clients’ products move through phases. It also gives us a strong understanding of each client’s product and process, which we may have developed, adding huge value when it comes to increased batch outputs and meeting clinical deadlines. 

    White, Piramal: Demand for hi-tech capabilities should grow as ADCs and other high value products predominate the potent development space. Approximately 119 traditional cytotoxic compounds are being developed, nearly all represent new formulations of older known cytotoxic APIs. Many are liposomal and nanoparticle delivery systems thus supporting the need for hi-tech capabilities. In addition, continued generic demand is being driven by the drugs in shortage in the U.S.; 77% of the drugs in shortage are injectable drugs. Also, there will be greater price pressures as CDMOs in emerging markets become a greater threat to U.S. and EU competitors.

    Schroeder, PCI: We see increasingly that new drugs are being developed for very specialized disease states and unmet needs. This translates to much smaller batch sizes and smaller patient populations, which has a significant impact on operations and the technologies that are the best fit for the application. We have focused on flexible equipment friendly to frequent changeover and redeployment.

    There is also a shift from clinical administration to in-home administration by the patient, which drives the push towards patient convenience in delivery form, namely prefilled syringes, pens and autoinjectors, as well as metered deliveries such as infusions and wearable devices. Packaging operations are certainly becoming more complex and specialized, with a need for real precision and automated quality inspection. Having a deep experience supporting various parenteral delivery forms allows us to support our clients with best practices and solutions to ensure success.

    Palus, LSNE: The demand for highly potent/cytotoxic processing has continued to grow, along with the increase in the ADC market. A number of CMOs have added this capability over the last couple of years but there still does seem to be some shortage in available capacity. 

    The number of biologic INDs is increasing faster than the number of small molecule INDs. Specifically, the field of oligonucleotides is rapidly expanding with the number of companies developing antisense, siRNA, and RNAi technologies. Many products within this class of therapeutics lack of stability in an aqueous solution and many companies are turning to lyophilization to increase shelf life. These high value APIs should also benefit from reliable equipment with redundant systems. Many of these new APIs are extremely expensive. It is important to minimize the risk of loss both through the implementation of an efficient production process and having redundant equipment to support the manufacture of such products.

    As new solubilization technologies become available, many low solubility APIs have been able to enter the market. A CMO needs to stay abreast of these technologies to support liposomal formulations, emulsions, suspensions, etc. Many companies have developed platform technologies, which are used for many products within the company’s pipeline. CMOs working collaboratively with the developer on complex/aseptically processed projects are driving the business towards long term partnerships rather than one-off fills. 

    CP: What are the key new technology innovations making an impact?
    Delauney, Catalent: Blow-fill-seal (BFS) technology offers an alternative to filling into traditional glass vials and can demonstrate advantages over the use of glass itself, and in reducing the risk of particulate contamination, because with BFS the container is formed, filled and sealed very quickly within a highly controllable space.
    Catalent has demonstrated that BFS is suitable for biologics, and has completed compatibility assessments of a model monoclonal antibody formulation in a BFS plastic vial, compared and a glass vial, with good results.

    Anderson, Symbiosis: Single-use, disposable technologies form the foundation of all that we do at Symbiosis and help us to achieve absolute compliance by eliminating potential for cross-contamination.

    Schroeder, PCI: There is a real focus on patient safety and convenience for injectable products, which will support more personal administration and allow patients to not feel tied to the home or clinic due to their medication regimen.  The developments in safety syringes and pen/autoinjector technologies make it much more convenient for patients to live a normal lifestyle, which is a tremendous development for everyone. Likewise, the inherent fragility of parenteral delivery forms is being addressed through advanced materials, further benefitting the patient. Similarly, needle technologies are rapidly advancing to provide patients a more enjoyable experience in taking their medication without discomfort.

    Palus, LSNE: The industry is continuing to evolve and there have been many new technology innovations that have impacted the CMO industry. Since we are a multi-use facility, we use disposable and single-use equipment whenever possible. These disposable materials reduce the risk of cross contamination and protect both our facility and our operators. There has also been a focus on producing pharmaceutically elegant products at an earlier stage than was expected in the past, so LSNE’s development team continues to add new technologies to better serve our clients. Additionally, LSNE has brought on UPLC capabilities which provide more sensitive analysis in a much shorter time compared to traditional HPLC. 
    Suggested For You
    Symbiosis Symbiosis
    Asymchem Asymchem
    PCI Pharma Services PCI Pharma Services
    Piramal Pharma Solutions Piramal Pharma Solutions
    Bora Pharmaceuticals Bora Pharmaceuticals
    Samsung Biologics Breaks Ground on Samsung Biologics Breaks Ground on 'Super Plant'
    Dalton Pharma Services Expands Capabilities Dalton Pharma Services Expands Capabilities
    Argonaut Manufacturing Services Completes First cGMP Run Argonaut Manufacturing Services Completes First cGMP Run
    Vetio Animal Health Vetio Animal Health
    LSNE, Selecta Biosciences Form Mfg. Pact LSNE, Selecta Biosciences Form Mfg. Pact
    Permira Funds Acquires LSNE Permira Funds Acquires LSNE
    LSNE Completes Two FDA Inspections LSNE Completes Two FDA Inspections
    Gerresheimer Presents Solutions for Sensitive Drugs Gerresheimer Presents Solutions for Sensitive Drugs
    PCI to Discuss Key Trends PCI to Discuss Key Trends
    PCI Names Ops Director at Tredegar Site PCI Names Ops Director at Tredegar Site

    Related Features

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    • Selecting the Right Outsourcing Model for Emerging Biotech

      Selecting the Right Outsourcing Model for Emerging Biotech

      Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
      Timothy King and Elisha Talley-Roithner, PPD 01.27.21


    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21


    • Communicating Your Contracting Priorities to Your Drug Company Customers

      Communicating Your Contracting Priorities to Your Drug Company Customers

      A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
      Stephen Sayre, Dykema 01.27.21

    • COVID-19 Impact Report

      COVID-19 Impact Report

      Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
      Tim Wright, Editor, Contract Pharma 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21


    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Mule-Hide Products Co. Promotes Steven Litaker to Territory Manager
    Terra Firma, Wanhua Announce New Distribution Partnership
    Gelest CEO Elected to National Academy of Engineering
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login